Trial Profile

Phase IIa trial of three dosages of fedovapagon in patients with nocturia associated with benign prostatic hyperplasia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Jul 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fedovapagon (Primary)
Indications Benign prostatic hyperplasia; Lower urinary tract symptoms; Nocturia
Focus Therapeutic Use
Sponsors Vantia Therapeutics

Most Recent Events

03 Jun 2010 Results reported at 105th Annual Meeting of the American Urological Association.
29 Jun 2009 Positive results reported in Vantia Therapeutics media release.
24 Mar 2009 Status changed from recruiting to completed, according to a Vantia Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com